Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shrimp: Hydroxocobalamin Tolerability in Healthy Individuals
NCT07469189Phase 1Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Jan 2023
- Primary completion
- Jun 2023
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hydroxocobalamin in ulcerative colitis (UC), Primary Sclerosing Cholangitis (PSC) and pouchitis, sponsored by Brigham and Women's Hospital. Primary endpoint: Adverse Events at 2 weeks. Started Jan 2023; status: completed.
02
Drugs
hydroxocobalamin
03
Conditions
ulcerative colitis (UC)Primary Sclerosing Cholangitis (PSC)pouchitis
Beyond the preview
Go deeper on NCT07469189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07469189.